JD({"d":"<div class='nfeed'><b id='dtspecial'>00:00<\/b> <font style='font-weight:bold'>Biophore India Receives Licences To Market Covid Durg Molnupiravir<\/font><br><div>Biophore India Pharmaceuticals on Thursday said it has received licences from Medicines Patent Pool (MPP) on behalf of originator company MSD to manufacture and market molnupiravir for treatment of COVID-19 and will launch in India next week priced at Rs 1,500 for a pack of 40 capsules.<\/div><div><br><\/div><div>The licences are applicable for both active pharmaceutical ingredients (API) and finished product in capsules form. It enables the company to launch the product within India as well as export to 104 other countries around the world, Biophore India Pharmaceuticals said in a statement.<\/div><div><br><\/div><div><i><b>(PTI)<\/b><\/i><br><\/div><\/div>","entype":"Text","h":"","img":"","imgalt":"","imgcaption":"","key":"False","link":"","s":28,"sub":"","t":"Jan 20, 2022-22:26:43","title":"<div>Biophore India Pharmaceuticals on Thursday said it has received licences from Medicines Patent Pool (MPP) on behalf of originator company MSD to manufacture and market molnupiravir for treatment of COVID-19 and will launch in India next week priced at Rs 1,500 for a pack of 40 capsules.<\/div><div><br><\/div><div>The licences are applicable for both active pharmaceutical ingredients (API) and finished product in capsules form. It enables the company to launch the product within India as well as export to 104 other countries around the world, Biophore India Pharmaceuticals said in a statement.<\/div><div><br><\/div><div><i><b>(PTI)<\/b><\/i><br><\/div>","type":"nfeed"});